AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Orion Oyj

Report Publication Announcement Jul 17, 2023

3232_fs_2023-07-17_ee6b36ed-0a73-489f-8f19-42003c45385e.html

Report Publication Announcement

Open in Viewer

Opens in native device viewer

Disclosure 435192

Orion - Financial Calendar

Orion Corporation's financial reporting and Annual General Meeting in 2024

ORION CORPORATION

STOCK EXCHANGE RELEASE – FINANCIAL CALENDAR

17 JULY 2023 at 11.00 EEST

Orion Corporation's financial reporting and Annual General Meeting in 2024

Orion Corporation will publish its Financial Statement Release 2023 on Tuesday, 13 February 2024.

The publication dates of the Interim Reports and the Half-Year Financial Report in 2024 are as follows:

Interim Report January-March 2024

Half-Year Financial Report January-June 2024

Interim Report January-September 2024
Thursday, 25 April 2024

Thursday, 18 July 2024

Tuesday, 29 October 2024

The Financial Statements and the Report of the Board of Directors for 2023 will be published on the Company's website at the latest in week 9/2024.

The Annual General Meeting is planned to be held on Wednesday, 20 March 2024.

Orion's financial reports and related presentation material are available on the Group's website at http://www.orion.fi/investors promptly after the publishing. The website also provides a possibility to register on Orion's mailing lists for releases.

Orion Corporation

Liisa Hurme



President and CEO
Olli Huotari



SVP, Corporate Functions

Contact person:

Tuukka Hirvonen, Investor Relations, Orion Corporation

tel. +358 10 426 2721

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland

http://www.orion.fi/en

http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

Talk to a Data Expert

Have a question? We'll get back to you promptly.